SCHEMBL7027366

SCHEMBL7027366

COc1cc(CO)c(C2=CCN(C)CC2)c(O)c1C(=O)/C=C/c1ccc(O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.47
TTR P02766 1/20 0.47
ALOX5 P09917 1/20 0.47
NFKB1 P19838 1/20 0.47
DPP4 P27487 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
ESR1 P03372 1/20 0.45
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
ABCG2 Q9UNQ0 2/20 0.42
CAPN1 P07384 1/20 0.42
PARP1 P09874 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
ABCB1 P08183 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7028113 0.94 MAPT (0.43) PDPK1TTRALOX5NFKB1DPP4
SCHEMBL7030660 0.94 TDP1 (0.50) NFKB1DPP4NFKB2RELATDP1
SCHEMBL7029104 0.93 TP53 (0.43) PDPK1TTRALOX5TDP1MAPT
SCHEMBL7026784 0.93 ABCB1 (0.49) PDPK1TTRALOX5TDP1MAPT
SCHEMBL7026486 0.93 MAPT (0.53) MAPTNPSR1MAOAMAOBABCB1
SCHEMBL7028278 0.91 ABCB1 (0.51) MAPTNPSR1ABCG2MAOAMAOB
SCHEMBL745937 0.91 NFKB1 (0.50) PDPK1TTRALOX5NFKB1DPP4
SCHEMBL7027458 0.91 ABCB1 (0.41) PDPK1TTRALOX5TDP1MAPT
SCHEMBL13075866 0.90 NFKB1 (0.52) PDPK1TTRALOX5NFKB1DPP4
SCHEMBL7028325 0.89 ABCB1 (0.48) MAPTKDM4ELMNAABCG2ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER SHANDONG UNIVERSITY (CN) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER CDK6, CDK5, CDK4 PDPK1 197/4885TTR 4479/4885ALOX5 2088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.